Cut-off points (CP), and sensitivity and specificity rates (%) for development and validation of the screening instrument
| CP | Men | Women | ||
|---|---|---|---|---|
| Se (CI) | Sp (CI) | Se (CI) | Sp (CI) | |
| Se, sensitivity; Sp, specificity. 95% CI in parentheses. | ||||
| Development of the screening instrument | ||||
| 3 | 15.3 (9.8–22.8) | 97.3 (96.8–97.6) | 11.9 (6.2–21.2) | 97.4 (96.6–98.0) |
| 5 | 22.9 (16.2–31.2) | 95.3 (94.7–95.8) | 22.6 (14.5–33.3) | 95.6 (94.6–96.5) |
| 6 | 26.7 (19.5–35.3) | 94.4 (93.8–95.0) | 32.1 (22.6–43.3) | 95.0 (94.0–95.8) |
| 8 | 33.4 (25.7–42.4) | 92.5 (91.8–93.1) | 34.5 (24.7–45.8) | 93.0 (91.9–94.1) |
| 10 | 38.9 (30.7–47.9) | 90.6 (89.9–91.4) | 41.7 (31.2–52.9) | 91.3 (90.0–92.4) |
| 20 | 58.8 (49.8–67.2) | 80.7 (80.0–81.7) | 57.1 (45.9–67.7) | 81.3 (79.5–82.9) |
| 30 | 71.0 (62.3–78.4) | 70.9 (69.7–72.1) | 67.9 (56.7–77.4) | 71.5 (69.5–73.5) |
| 40 | 80.2 (72.1–86.4) | 60.9 (60.0–62.1) | 78.6 (68.0–86.5) | 61.4 (59.2–63.5) |
| Validation of the screening instrument | ||||
| 3 | 6.9 (3.7–12.3) | 97.6 (97.2–98.0) | 1.1 (0.0–7.0) | 98.5 (97.7–99.0) |
| 5 | 9.4 (5.6–15.4) | 96.5 (95.9–97.0) | 6.5 (2.6–14.1) | 97.4 (96.5–98.1) |
| 6 | 10.1 (6.0–16.1) | 95.9 (95.2–96.4) | 7.5 (3.3–15.4) | 96.1 (95.1–97.0) |
| 8 | 13.8 (9.1–20.4) | 94.2 (93.5–94.8) | 7.5 (3.3–15.4) | 94.5 (93.3–95.5) |
| 10 | 17.6 (12.2–24.6) | 92.4 (91.6–93.1) | 10.8 (5.6–19.3) | 92.8 (91.4–94.0) |
| 20 | 35.8 (28.5–43.9) | 84.9 (83.8–85.9) | 24.7 (16.6–35.0) | 84.0 (82.2–85.7) |
| 30 | 49.1 (41.1–57.1) | 76.3 (75.1–77.5) | 36.6 (27.0–47.2) | 73.6 (71.4–75.7) |
| 40 | 56.6 (48.5–64.4) | 68.1 (66.8–69.4) | 54.8 (44.2–56.0) | 65.2 (62.9–67.5) |